Balyasny Asset Management
IOVA icon

Balyasny Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Balyasny Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-300,000
Closed -$9.88M – 1514
2020
Q3 		$9.88M Buy
+300,000
New +$9.2M 0.07% 386

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Balyasny Asset Management's IOVA Position: Q1 2026 in Review

Balyasny Asset Management increased its Iovance Biotherapeutics (IOVA) stake by 266% in Q1 2026, buying an estimated $578K and bringing the position to 248,764 shares worth $873K. The position accounts for ﹤0.01% of the portfolio, ranked #2136.

Balyasny Asset Management first reported a position in IOVA in Q2 2018 and has held it in 27 quarters since. The position peaked at $42M in Q3 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Balyasny Asset Management held 248,764 shares of Iovance Biotherapeutics worth $873K as of Q1 2026.
  • Balyasny Asset Management bought 180,726 Iovance Biotherapeutics shares in Q1 2026, an estimated $578K.
  • Iovance Biotherapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2136 holding.
  • Balyasny Asset Management first reported a position in Iovance Biotherapeutics in Q2 2018 and has held it in 27 quarters since.
  • Balyasny Asset Management's Iovance Biotherapeutics position peaked at $42M in Q3 2024.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.